Campath Related Clinical Trials
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia [Recruiting]
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia [Recruiting]
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma [Recruiting]
Alemtuzumab + Rituximab Consolidation in CLL [Recruiting]
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Alemtuzumab (Campath(Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia [Recruiting]
Campath in Chronic GVHD [Recruiting]
Alemtuzumab to Treat Severe Aplastic Anemia [Recruiting]
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma [Recruiting]
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia [Recruiting]
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases [Recruiting]
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Recruiting]
Campath, Chronic Lymphocytic Leukemia (CLL), Safety Confirmatory Study [Not yet recruiting]
Alemtuzumab and CHOP in T-cell Lymphoma [Recruiting]
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL [Recruiting]
Simultaneous Pancreas-Kidney Transplantation With Campath Protocol [Not yet recruiting]
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP [Recruiting]
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia [Recruiting]
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias [Recruiting]
|
